cPFS univariable | cPFS multivariable | OS univariable | OS multivariable | |||||||||
HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | |
Primary tumor type | ||||||||||||
Acral or mucosal vs cutaneous or unknown | 1.57 | 1.09 to 2.26 | 0.016 | 1.85 | 1.23 to 2.79 | 0.003 | 1.84 | 1.23 to 2.76 | 0.003 | 2.13 | 1.36 to 3.34 | 0.001 |
Genomic subtype | ||||||||||||
BRAF or NRAS mt vs WT | 1.28 | 0.94 to 1.77 | 0.120 | 1.40 | 0.99 to 1.96 | 0.056 | 1.16 | 0.81 to 1.65 | 0.423 | 1.46 | 1.00 to 2.13 | 0.052 |
Anti-PD1 regimen | ||||||||||||
PD1+CTLA4 vs PD1 | 0.63 | 0.45 to 0.90 | 0.011 | 0.57 | 0.38 to 0.86 | 0.007 | 0.60 | 0.40 to 0.90 | 0.014 | 0.42 | 0.28 to 0.65 | <0.001 |
Line of therapy | ||||||||||||
First vs second or later | 0.56 | 0.42 to 0.76 | <0.001 | 0.72 | 0.51 to 1.01 | 0.062 | 0.53 | 0.38 to 0.75 | <0.001 | – | ||
No of metastatic sites | ||||||||||||
>3 vs ≤3 | 2.15 | 1.56 to 2.98 | <0.001 | 2.06 | 1.47 to 2.88 | <0.001 | 2.23 | 1.56 to 3.18 | <0.001 | 2.16 | 1.50 to 3.11 | <0.001 |
M-stage | ||||||||||||
M1c/1d vs M0/1a/1b | 1.45 | 1.06 to 2.00 | 0.022 | – | 1.79 | 1.24 to 2.57 | 0.002 | – | ||||
LDH | ||||||||||||
≥1.5X ULN vs <1.5 x | 1.83 | 1.32 to 2.54 | <0.001 | 1.49 | 1.06 to 2.11 | 0.023 | 2.41 | 1.68 to 3.46 | <0.001 | 1.88 | 1.28 to 2.76 | <0.001 |
NLR | ||||||||||||
≥5 vs <5 | 1.39 | 0.98 to 1.96 | 0.062 | – | 1.72 | 1.19 to 2.51 | 0.004 | 1.59 | 1.06 to 2.36 | 0.023 | ||
Age | ||||||||||||
≥60 vs <60 | 0.83 | 0.61 to 1.11 | 0.215 | – | 1.21 | 0.86 to 1.71 | 0.267 | – | ||||
Gender | ||||||||||||
Male vs female | 0.78 | 0.58 to 1.06 | 0.114 | – | 0.82 | 0.58 to 1.15 | 0.254 | – |
cPFS, clinical progression-free survival; LDH, lactate dehydrogenase; NLR, neutrophil to lymphocyte ratio; OS, overall survival.